GLP-1 clinical trials in Indiana: 18 recruiting now

18 GLP-1 clinical trials are recruiting at 29 sites in 11 cities across Indiana. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Indiana

1. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

   Who can join. Adults 18+, have psoriasis, BMI 27+.

   2 sites in Indiana

   • Dawes Fretzin Clinical Research Group, LLC, Indianapolis. 317-516-5030
   • The Indiana Clinical Trials Center, PC, Plainfield. 317-837-6082

2. Fibrosis Lessens After Metabolic Surgery

   Phase 4. Run by The Cleveland Clinic. Registry number NCT06374875.

   A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

   Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

   1 site in Indiana

   • Indiana University, Indianapolis

3. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

   Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

   Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

   1 site in Indiana

   • Lake Cumberland Rheumatology, New Albany. 5024953665

4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   4 sites in Indiana

   • Indiana University Health University Hospital, Indianapolis. 317-278-1652
   • Gastroenterology Health Partners, New Albany. 812-206-1702
   • Deaconess Clinic- Gateway, Newburgh. 812-490-4505
   • Digestive Research Alliance of Michiana, South Bend. 574-904-9617

5. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

   Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

   4 sites in Indiana

   • ASHA Clinical Research - Munster, LLC, Hammond. 219-803-6649
   • Indiana University Health Methodist Hospital, Indianapolis
   • Cardiovascular Research of Northwest Indiana, Munster. 219-934-4200
   • Deaconess Clinic- Gateway, Newburgh. 812-490-4505

6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   2 sites in Indiana

   • ASHA Clinical Research - Munster, LLC, Hammond. 833-602-2368
   • Digestive Research Alliance of Michiana, South Bend. 833-602-2368

7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

   2 sites in Indiana

   • ASHA Clinical Research - Munster, LLC, Hammond. 833-602-2368
   • Digestive Research Alliance of Michiana, South Bend. 833-602-2368

8. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

   Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

   2 sites in Indiana

   • Indiana University Health University Hospital, Indianapolis
   • Gastroenterology Health Partners, New Albany. 812-206-1702

9. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

   Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

   2 sites in Indiana

   • Indiana University Health University Hospital, Indianapolis
   • Gastroenterology Health Partners, New Albany. 812-206-1702

10. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06439277.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Indiana

    • Indiana University Health University Hospital, Indianapolis

11. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Indiana

    • Riley Hospital for Children, Indianapolis

12. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in Indiana

    • IU Health - Riley Physicians Endo-Diab, Indianapolis

13. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Indiana

    • Research Site, Evansville

14. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Indiana

    • Velocity Clin. Res Valparaiso, Valparaiso

15. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Indiana

    • Investigators Research Group, Brownsburg. 317-852-8280

16. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Indiana

    • Midwest Inst For Clin Res, Indianapolis

17. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Indiana

    • Midwest Inst For Clin Res, Indianapolis

18. Slowly Digestible Carbohydrates for GLP-1 Secretion

    Run by Purdue University. Registry number NCT07572513.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 45, have healthy participant study, BMI 18.5+.

    1 site in Indiana

    • Clinical Research Center at Purdue University, West Lafayette. 765-496-6275

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact